Search Result

Results for "

MAGL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MAGL (34) Autophagy (1) Calcium Channel (1) Cannabinoid Receptor (2) FAAH (9) Histamine Receptor (1) Necroptosis (1) Phospholipase (1)
By Research Areas:	Cancer (4) Inflammation/Immunology (8) Metabolic Disease (5) Neurological Disease (24)

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Antibodies

Targets Recommended: MAGL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111538

MAGL-IN-1	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of *MAGL, with an IC₅₀* of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .

HY-132310

MAGL-IN-4	MAGL	Neurological Disease
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .

HY-163202

MAGL-IN-13	MAGL Calcium Channel	Neurological Disease Cancer
MAGL-IN-13 (compound (3R, 4S) - 5v) is a selective, irreversible inhibitor for *MAGL*,with IC₅₀ values of 0.026, 0.021 and 0.24 nM for mMAGL, hMAGL and rMAGL, respectively. MAGL-IN-13 can penetrant blood brain barrier. .

HY-157040

MAGL-IN-9

MAGL Inflammation/Immunology

MAGL-IN-9 (compound 16) is a selective and reversible MAGL inhibitor with IC₅₀ 2.7 nM .

MAGL-IN-9	MAGL	Inflammation/Immunology
MAGL-IN-9 (compound 16) is a selective and reversible *MAGL* inhibitor with IC₅₀ 2.7 nM .

HY-116143

MAGL-IN-12	MAGL	Metabolic Disease
SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC₅₀s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .

HY-157042

MAGL-IN-11	MAGL	Inflammation/Immunology Cancer
MAGL-IN-11 (compound 29) is a selective and reversible MAGL inhibitor. MAGL-IN-11 has the potential to study inflammation, cancer and antioxidants .

HY-145945

MAGL-IN-6	MAGL	Neurological Disease
MAGL-IN-6 is a potent *MAGL* inhibitor with an IC₅₀ of 4.71 nM. MAGL-IN-6 can be used for neurological disorders research (WO2020065613A1; example 234) .

HY-157041

MAGL-IN-10	MAGL	Cancer
MAGL-IN-10 is areversible monoacylglycerol lipase (MAGL) inhibitor with very good ADME properties and low in vivo toxicity.MAGL-IN-10 can be used for the research ofcancer, neurological disorders and inflammatory pathologies .

HY-157038

MAGL-IN-8

MAGL Inflammation/Immunology

MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC₅₀ of 2.5 ± 0.4 nM for hMAGL .

MAGL-IN-8	MAGL	Inflammation/Immunology
MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC₅₀ of 2.5 ± 0.4 nM for hMAGL .

HY-162315

MAGL-IN-16	MAGL	Neurological Disease
MAGL-IN-16 (compound 27) is an oral active, selective and reversible *MAGL* inhibitor with the IC₅₀ value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress .

HY-162305

MAGL-IN-15	MAGL	Neurological Disease
MAGL-IN-15 (Compound 6) is a *MAGL* inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities .

HY-162304

MAGL-IN-14

MAGL Neurological Disease

MAGL-IN-14 (compound 2) is a potent inhibitor of MAGL, with IC₅₀ of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively .

MAGL-IN-14	MAGL	Neurological Disease
MAGL-IN-14 (compound 2) is a potent inhibitor of *MAGL, with IC₅₀* of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively .

HY-119283

MAGL-IN-5 1 Publications Verification CAY10499	MAGL FAAH	Metabolic Disease
MAGL-IN-5 (CAY10499) is a non-selective lipase inhibitor with IC₅₀ values of 144, 90, and 14 nM for human recombinant monoacylglycerol lipase(MAGL),hormone sensitive lipase(HSL), and fatty acid amide hydrolase(FAAH) respectively .

HY-150702

MAGLi 432	MAGL	Neurological Disease Inflammation/Immunology
MAGLi 432 is a non-covalent, potent, highly selective, and reversible *MAGL* inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .

HY-146342

*FAAH/MAGL-IN-3*	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC₅₀ values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-143263

*FAAH/MAGL-IN-1*	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-1 (compound SIH 3) is a potent FAAH and *MAGL* inhibitor with IC₅₀s of 31 nM and 29 nM, respectively. FAAH/MAGL-IN-1 has the potential for the research of neuropathic pain .

HY-143264

*FAAH/MAGL-IN-2*	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier FAAH and *MAGL* inhibitor with IC₅₀s of 11 nM and 36 nM (K_is of 28 nM and 60 nM), respectively . FAAH/MAGL-IN-2 has the potential to research neuropathic pain without causing locomotion impairment .

HY-118158

*FAAH/MAGL-IN-4*	FAAH	Neurological Disease
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .

HY-77491

FAAH/MAGL-IN-5

FAAH MAGL Neurological Disease

AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects .

*FAAH/MAGL-IN-5*	FAAH MAGL	Neurological Disease
AM6701 is a potent *FAAH/MAGL* inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects .

HY-163092

LEI-515	MAGL Necroptosis	Inflammation/Immunology
LEI-515 is a first-in-class peripherally restricted, reversible *MAGL* inhibitor. LEI-515 increases 2-AG levels in peripheral organs, but not mouse brain. LEI-515 attenuated liver necrosis, oxidative stress and inflammation in a CCl4-induced acute liver injury model .

HY-121422

JZP-361	MAGL Histamine Receptor	Inflammation/Immunology
JZP-361 is a potent, reversible and selective inhibitor of human recombinant *MAGL* (hMAGL) with an IC₅₀ of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .

HY-12332

JW 642 1 Publications Verification	MAGL	Neurological Disease
JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.

HY-15249

JZL 184 2 Publications Verification	MAGL	Neurological Disease
JZL 184 is a potent, selective and irreversible *MAGL* inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC₅₀ of 8 nM). JZL 184 displays >300-fold selectivity for *MAGL* over FAAH .

HY-108613

JJKK 048

1 Publications Verification

MAGL Neurological Disease

JJKK 048 is an ultrapotent and highly selective inhibitor of Monoacylglycerol lipase (MAGL).
HY-111512

PF-06795071

MAGL Neurological Disease Inflammation/Immunology

PF-06795071 is a potent and selective covalent MAGL inhibitor with an IC₅₀ of 3 nM .

JJKK 048 1 Publications Verification	MAGL	Neurological Disease
JJKK 048 is an ultrapotent and highly selective inhibitor of Monoacylglycerol lipase (MAGL).

PF-06795071	MAGL	Neurological Disease Inflammation/Immunology
PF-06795071 is a potent and selective covalent *MAGL* inhibitor with an IC₅₀ of 3 nM .

HY-18977

KML29 2 Publications Verification	MAGL	Metabolic Disease Inflammation/Immunology
KML29 is an extremely selective, orally active and irreversible *MAGL* inhibitor, with IC₅₀ values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH .

HY-136562

N-Arachidonyl maleimide

MAGL Metabolic Disease

N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC₅₀ value of 140 nM .

N-Arachidonyl maleimide	MAGL	Metabolic Disease
N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC₅₀ value of 140 nM .

HY-117632

Elcubragistat 1 Publications Verification ABX-1431	MAGL	Neurological Disease
Elcubragistat (ABX-1431) is a highly potent, selective, and orally available, CNS-penetrant monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 14 nM.

HY-15250

JZL195 4 Publications Verification	FAAH MAGL Autophagy	Neurological Disease
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 2 and 4 nM, respectively .

HY-103463

SA57	FAAH MAGL	Neurological Disease
SA57 is a potent, selective FAAH inhibitor with IC₅₀s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases *MAGL* (IC₅₀s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC₅₀ of 850 nM), but not other brain serine hydrolases .

HY-116141

7-Hydroxycoumarinyl arachidonate 7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate	Phospholipase MAGL	Others
7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer .

HY-146341

FAAH-IN-5	FAAH MAGL	Neurological Disease
FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-133130

JNJ-42226314	MAGL	Neurological Disease
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .

HY-117474

MJN110 2 Publications Verification	MAGL	Neurological Disease
MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity .

HY-120851

O-7460	Cannabinoid Receptor	Metabolic Disease
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .

HY-152152

JZP-MA-13	MAGL	Neurological Disease
JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .

HY-130311

2-Linoleoyl glycerol 2-Monolinolein; 2-Monolinoleoylglycerol	Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Cat. No.	Product Name

HY-L091

Lipid Metabolism Compound Library	650 compounds
Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation. MCE offers a unique collection of 650 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Lipid Metabolism Compound Library

650 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 650 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Species:	Human (2) Rat (1)
Tag:	His (2) Tag Free (1)
Source:	P. pastoris (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701985

	MGLL Protein, Human (His) MGLL; Monoglyceride lipase; MGL; HU-K5; Lysophospholipase homolog; Lysophospholipase-like; Monoacylglycerol lipase; MAGL	Human	E. coli
	MGLL proteins convert monoacylglycerides into free fatty acids and glycerol. MGLL Protein, Human (His) is the recombinant human-derived MGLL protein, expressed by E. coli , with N-6*His labeled tag. The total length of MGLL Protein, Human (His) is 302 a.a., .

HY-P701984

	MGLL Protein, Human MGLL; Monoglyceride lipase; MGL; HU-K5; Lysophospholipase homolog; Lysophospholipase-like; Monoacylglycerol lipase; MAGL	Human	E. coli
	MGLL proteins convert monoacylglycerides into free fatty acids and glycerol. MGLL Protein, Human is the recombinant human-derived MGLL protein, expressed by E. coli , with tag free. The total length of MGLL Protein, Human is 302 a.a., .

HY-P71755

	Monoglyceride lipase Protein, Rat (P.pastoris, His) Mgll; Mgl2; Monoglyceride lipase; MGL; Monoacylglycerol lipase; MAGL	Rat	P. pastoris
	Monoglyceride lipase is a key enzyme in lipid metabolism and plays a key role in converting monoacylglycerols into free fatty acids and glycerol, contributing to important cellular processes. In addition to being involved in lipid metabolism, this enzyme also hydrolyzes the endocannabinoid 2-arachidonoylglycerol, thereby affecting the complex regulation of endocannabinoid signaling, nociception, and pain perception. Monoglyceride lipase Protein, Rat (P.pastoris, His) is the recombinant rat-derived Monoglyceride lipase protein, expressed by P. pastoris , with N-His labeled tag. The total length of Monoglyceride lipase Protein, Rat (P.pastoris, His) is 303 a.a., with molecular weight of ~35.5 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P83201

Monoacylglycerol Lipase Antibody (YA2946)

HUK5; Lysophospholipase homolog; Lysophospholipase like; MAGL; MGL; MGLL; Monoacylglycerol lipase
WB Human

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: